Digital & Innovation
First approved wearable watch and patch for non-invasive cuffless monitoring of blood pressure
Biobeat, a bio-medical technology company developing advanced sensing and remote monitoring solutions for patients, announced that the U.S. Food and Drug Administration (FDA) has granted a 510K clearance for its patch and watch for measurement of blood pressure, oxygenation and heart rate in hospitals, clinics, long-term care and at home. Biobeat’s products enable cloud-based healthcare with connectivity either through a smartphone or a dedicated gateway.
“This is the first cuffless blood pressure solution to be cleared by the FDA—no more need for an inflating cuff,” says Arik Ben Ishay, Founder and CEO of Biobeat. “This clearance opens tremendous opportunities for remote monitoring of vital signs of patients and we are excited that we can now also offer this in the US market,” continues Ben Ishay. Biobeat’s products have already been CE marked and approved as medical devices in Europe and Israel.
“Remote monitoring of patient’s vital sign requires completely different technological approaches than current practice,” says Biobeat’s Chief Medical Officer Prof. Arik Eisenkraft, MD. “While blood pressure, heart rate and oxygenation are the backbones of monitoring, we will continue to work with the FDA to approve additional parameters for our devices,” continues Prof. Eisenkraft.
“The promise of remote care for patients and the equally important continuum of care: connecting home-based, community and hospital care, will not happen without novel medical-grade sensors and we are proud to be the pioneers in this field,” says Dr. Dan J. Gelvan, Chairman of the Board.
You may also like Demystifying AI, machine learning and robotics in healthcare
News & Trends - Pharmaceuticals
Healthcare affordability and accessibility top priority for consumers ahead of Federal Budget
Pharma News: With the Federal Budget set to be delivered in just one week, there is a critical need for […]
MoreNews & Trends - Pharmaceuticals
UCB secures registration of rheumatology drug
Pharma News: UCB Australia has secured Therapeutic Goods Administration (TGA) approval of its therapy for psoriatic arthritis (PsA), non-radiographic axial […]
MoreDigital & Innovation
Targeted funding of digital health technologies key to unlocking $5 billion in savings: New report
Digital & Innovation: Integrating digital technology into healthcare more effectively could alleviate pressures on our healthcare system and lead to […]
MoreNews & Trends - MedTech & Diagnostics
Surgeons welcome ‘significant win’ for patients, amidst clash with health insurers
MedTech & Diagnostics News: The Royal Australasian College of Surgeons (RACS) is heralding a significant triumph for Australian patients following […]
More